< Back to previous page
Researcher
Eric Van Cutsem
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
1 - 10 of 13
- SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancersFrom1 Jan 2022 → TodayFunding: Foundations, funds and other with scientific goal
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
- TRP channels: translational research from bench to bedsideFrom10 Sep 2018 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- Genetic biomarkers for anti-angiogenic therapies - a translational approach.From1 Jan 2011 → 31 Dec 2013Funding: Private funding of national origin - undefined
- The role of the forkhead transcription factor FOXP1 in cancer.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Technical research platform & heavy equipment HiSeq200 (including CBOT computing system and warranty).From1 Sep 2010 → 31 Aug 2013Funding: Other federal scientific institutions
- Can response to Epidermal Growth Factor Receptor antibodies in patients with metastatic Colorectal Cancer be predicted? Advanced bio-informatics tools, integrating gene mutation, microarray and proteomics data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
- Imaging for early response prediction to EGF-receptor blocking monoclonal antibodies in combination therapy for colorectal cancer.From1 Jan 2009 → 31 Dec 2012Funding: IWT - TBM (Applied Biomedical Research)
- Can response to epidermal growth factor receptor antibodies in metastatic colorectal cancer be predicted? Advanced bio-informatics tools integrating gene mutation and microarray data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: Private funding of national origin - undefined
Publications
21 - 30 of 726
- Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142(2022)
Authors: Eric Van Cutsem
Pages: 1052 - 1060 - MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer(2022)
Authors: Eric Van Cutsem
- Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database(2022)
Authors: Eric Van Cutsem
Pages: 142 - 152 - Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study(2022)
Authors: Eric Van Cutsem
Pages: 3065 - + - Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel +/- Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(2022)
Authors: Eric Van Cutsem
Pages: 3686 - 3694 - MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (trial in progress)(2022)
Authors: Eric Van Cutsem
Pages: S734 - S735 - Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER(2022)
Authors: Eric Van Cutsem
Pages: S700 - S701 - Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study(2022)
Authors: Eric Van Cutsem
Pages: 3489 - 3498 - Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.(2022)
Authors: Eric Van Cutsem
Pages: 100517 - Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.(2022)
Authors: Eric Van Cutsem
Pages: OF1 - OF9